Henderson Group PLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 38.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,985,629 shares of the biopharmaceutical company’s stock after buying an additional 1,099,826 shares during the period. Pfizer makes up approximately 1.0% of Henderson Group PLC’s investment portfolio, making the stock its 15th largest position. Henderson Group PLC’s holdings in Pfizer were worth $134,973,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Bloom Tree Partners LLC purchased a new stake in Pfizer during the first quarter worth $35,682,000. Opus Point Partners Management LLC purchased a new stake in Pfizer during the first quarter worth $3,260,000. Citizens Financial Group Inc RI boosted its stake in Pfizer by 6.1% in the first quarter. Citizens Financial Group Inc RI now owns 381,226 shares of the biopharmaceutical company’s stock worth $11,300,000 after buying an additional 21,762 shares in the last quarter. Thomaspartners Inc. boosted its stake in Pfizer by 4.4% in the first quarter. Thomaspartners Inc. now owns 4,814,578 shares of the biopharmaceutical company’s stock worth $142,704,000 after buying an additional 202,518 shares in the last quarter. Finally, Mariner Wealth Advisors LLC boosted its stake in Pfizer by 31.2% in the first quarter. Mariner Wealth Advisors LLC now owns 169,724 shares of the biopharmaceutical company’s stock worth $5,031,000 after buying an additional 40,408 shares in the last quarter. 68.53% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer Inc. (NYSE:PFE) opened at 32.14 on Thursday. The stock’s 50 day moving average price is $31.95 and its 200 day moving average price is $34.15. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The firm has a market capitalization of $195.04 billion, a P/E ratio of 32.27 and a beta of 0.90.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by $0.01. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The company had revenue of $13.05 billion for the quarter, compared to analysts’ expectations of $13.05 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The company’s revenue was up 7.9% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post $2.41 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.73%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 106.20%.

COPYRIGHT VIOLATION WARNING: “Henderson Group PLC Raises Stake in Pfizer Inc. (PFE)” was published by Financial Market News and is owned by of Financial Market News. If you are accessing this report on another publication, it was stolen and reposted in violation of United States & international copyright & trademark laws. The correct version of this report can be viewed at http://www.financial-market-news.com/henderson-group-plc-raises-stake-in-pfizer-inc-pfe/1212473/.

A number of equities research analysts recently weighed in on PFE shares. Jefferies Group lowered their price target on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Argus restated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Sunday, August 28th. Bank of America Corp. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $44.00 target price on shares of Pfizer in a report on Thursday, August 18th. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and an average target price of $37.91.

In related news, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction on Friday, November 4th. The shares were sold at an average price of $30.05, for a total value of $552,619.50. Following the completion of the sale, the insider now owns 149,199 shares of the company’s stock, valued at approximately $4,483,429.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the sale, the insider now directly owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.